Adventrx Pharmac. Heisses Eisen ?

RELATED NEWS


Adventrx Pharma Reports Addl. Pre-Clinical Data For ANX-514


Adventrx Pharma Q3 Net Loss Narrows - Quick Facts


ADVENTRX To Stay Listed On AMEX, To Submit NDA For Cancer Drug By Year End - Update


ADVENTRX Pharma Issues Business Update Following Recent Financing Activity - Quick Facts


Adventrx Pharma Completes Registered Direct Offering Of About $11.3 Mln - Quick Facts
(RTTNews) - Within the next few days, Adventrx Pharmaceuticals Inc. (ANX: News ) is expected to submit its New Drug Application for ANX-530, a novel emulsion formulation of chemotherapy drug Navelbine (vinorelbine). If submitted, the filing will mark the first NDA submission for Adventrx' drug.

Navelbine, a branded formulation of vinorelbine, is approved in the U.S. to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer. According to the company, Navelbine, which, despite being a generic product for a number of years, still sells in excess of $200 million a year world-wide. Adventrx is planning to seek approval of ANX-530 for the same indications as Navelbine.

Adventrx has yet another late-stage product candidate ANX-514 (docetaxel emulsion for injection), a reformulation of the blockbuster chemotherapeutic agent, Taxotere.

Incorporated under the name Victoria Enterprises, Inc. in December 1995, the company began operations in 1996. The name was subsequently changed to "BioQuest, Inc." then to "Biokeys Pharmaceuticals, Inc." and finally to "ADVENTRX Pharmaceuticals, Inc." in May 2003. The company's common stock trades on the American Stock Exchange (Amex).

The company has incurred annual net losses since inception and has not generated any revenue from product sales to date. As mentioned earlier, the NDA for ANX-530 will be the first for the company if it is successfully filed.

As of September 30, 2009, the company had cash and cash equivalents of $3.2 million and in October raised $6 million from equity financing. The company, which has zero debt, believes that its cash on hand will be sufficient to permit it to continue operations through 2010.

ANX, which has been trading in the range of $0.07-$0.25 over the past twelve months, closed Friday's trading at $0.19.

In June 2009, the NYSE Amex notified the Company that it was not in compliance with the NYSE Amex's continued listing standards related to stockholders' equity. Through financing activity in 2009, ADVENTRX increased its stockholder's equity to approximately $6.7 million as of December 31, 2009, which exceeds continued listing standards related to stockholders' equity. In April 2010, the NYSE Amex notified the Company that, based on a review of publicly available information, ADVENTRX has resolved the continued listing deficiencies originally identified in the June 2009 letter. According to the April 2010 letter, the Company must demonstrate compliance with the continued listing standards for two consecutive quarters and/or by December 1, 2010, otherwise the NYSE Amex may initiate delisting procedures. In part as a result of a financing completed in January 2010, the Company anticipates complying with continued listing standards related to stockholders' equity at March 31, 2010.

The reverse stock split is intended to satisfy the NYSE Amex's determination in the June 2009 letter that it is appropriate for the Company to effect a reverse stock split to address its low price per share and that, if a reverse stock split is not completed within a reasonable amount of time, the NYSE Amex may initiate delisting procedures. The Company also believes that a higher share price could broaden ADVENTRX's appeal to investors, in addition to reducing per share transaction fees and certain administrative costs.

The reverse split will be effective upon the close of trading on Friday, April 23, 2010, and the Company's common stock will begin trading on a split adjusted basis on the NYSE Amex when the market opens on Monday, April 26, 2010. The reverse split will reduce the number of shares of the Company's common stock outstanding from approximately 257 million to approximately 10.3 million. Proportional adjustments will be made to ADVENTRX's outstanding stock options, warrants and other equity awards and to its equity compensation plans. Par value and the number of authorized shares of common stock will not change. The Company will not issue any fractional shares. Stockholders will receive cash in lieu of fractional shares to which they would otherwise be entitled.

Information for Stockholders regarding Reverse Stock Split

Registered holders of ADVENTRX common stock will receive a letter of transmittal shortly after the effective date of the reverse stock split with instructions for the exchange of their old stock certificates or the electronic adjustment of their holdings through the direct registration system, as applicable. American Stock Transfer and Trust Company will act as the exchange agent and can be contacted at (877) 2486417. Stockholders with shares in brokerage accounts will be contacted by their brokers with instructions.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals is a specialty pharmaceutical company whose product candidates are designed to improve the performance of existing cancer treatments by addressing limitations associated principally with their safety and use. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statements

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will not meet the NYSE Amex's stockholders' equity continued listing standards for two consecutive quarters and/or by December 1, 2010 and that the NYSE Amex staff will commence delisting proceedings; the risk of negative market reaction following announcement and/or implementation of the planned reverse stock split, resulting in stock price decline; the risk of unexpected delays in completing the reverse stock split; the risk that NYSE Amex will commence delisting proceedings based on a future low selling price per share; the risk that ADVENTRX will pursue development activities at levels or on timelines, or will incur unexpected expenses, that shortens the period through which it is able to comply with NYSE Amex continued listing requirements related to stockholders' equity; the risk that ADVENTRX will be unable to raise sufficient additional capital to continue to develop, seek regulatory approval of and commercialize its product candidates while maintaining compliance with NYSE Amex continued listing requirements related to stockholders' equity; the risk of difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ADVENTRX's lead product candidates; ADVENTRX's reliance on the performance of third parties to assist in the conduct of its bioequivalence trials, regulatory submissions, CMC activities and other important aspects of its product candidate development programs, and that such third parties may fail to perform as expected; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2009. ADVENTRX's public filings with the Securities and Exchange Commission are available at www.sec.gov/.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.

Toll, und vorher wurde erst einmal eine Kapitalerhöhung durchgeführt.
Da stehen einen ja die Nackenhaare zu Berge.

Bin zum Glück hier nur mit noch kleinen Posi. drin.Wenns weiter runter geht leg ich noch mal nach. Gruß

Das werde ich bestimmt nicht tun.
Bei einen R/S sind die Kurse immer danach stark gefallen.
Hier geht nur noch eins, raus!!!

naja...Bei Genta ist nach dem ReSplit der Kurs gestiegen....
Aber das hier ist echter Murx....

Ich hab zwar keine Ahnung was jetzt die Tage passiert, Allerdings sind meine Aktien momentan aktuell Stand 26.4.2010 13.10Uhr gesperrt und können nicht verkauft werden.

Hat jmd eine Ahnung was hier weiter vor sich geht ?

Hängt mit dem Resplit zusammen der Heute ist. Gruß

Okee, wusste nicht dass die dann gänzlich nicht handelbar sind. Danke dir!

Laut der Postbank werden aus 4 =  1 neue ,

der Kurs war vorher bei 0,15 steht aber zur Zeit bei 3,10.

Das wäre ja eine schöne Geldvermehrung für uns !

Im Forum steht aber :

has approved a 1-for-25 reverse split of its common stock.

also ist wohl das Schreiben von der Postbank verkehrt !

www.finanznachrichten.de/...djusted-basis-begins-today-008.htm

Adventrx Pharma (AMEX:ANX) expects to resubmit its NDA during 4Q10 with required stability data following a refusal to file letter (RTF) issued by the FDA on 3/1/10 in response to the Company's original December 2009 submission for EXELBINE (ANX-530) (vinorelbine injectable emulsion).

beta.barchart.com/opinions/ANX

neue WKN  A1CWVV

Das teil hier ist ja billiger als Genta ! Hoffst du hier auf 10.000% ? Schätze mal,wenn das hier nix wird mit NDA,dann wird das bei Genta mit Tesetaxel auch nix ......

Viel glück!

MFG
Chali

Schauen wir mal...Bin vor dem ReSplit raus und schaue mir das ganze erst einmal von der Seitenlinie an...

ANX 2.95, geht ganz gut letzten Tage... :)

www.stockcharts.com/c-sc/...p;id=p31132975060&a=237391930" style="max-width:560px" />

das ist einer der Werte die still und leise beachtlich steigen...

$$$$

:-)

das ist doch schön... keine Hektik, keine Auseinandersetzungen... prima...

Das ist das Datum für die erhoffte Zulassung von"EXELBINE". Diesen möglichen Event  wollen sich viele  nicht entgehen lassen.Sollte die Zulassung bestätigt werden,wird das der Aktie einen starken Schub geben.Ohne Zulassung wird sie wieder abstürzen.

wow, traumhafter Chart :-)

Glückwunsch allen!

sorry, hab die threads wieder mal nicht synchronisiert... Netz gegangen $.53

original link:
investorshub.advfn.com/boards/read_msg.aspx?message_id=65097645


TH $.65 soweit, bids .612, rasche +15% in Tasche :-) $$$

wow... das ist doch was feines... :-)

40% in 3 Tagen... wow...

immer wieder einen trade wert die gute ANX...